Silver has gone on an absolute tear, surging over 5% intraday today, breaking decisively above the key $90 psychological level and reaching an intraday high of $91.57.As a result, silver ETFs surged in premarket trading. The 2× leveraged silver ETF $ProShares Ultra Silver(AGQ)$ jumped 8.17%, while the largest silver ETF, $iShares Silver Trust(SLV)$ , rose 4.08%, and $Abrdn Silver ETF Trust(SIVR)$ gained 3.96%.On the macro front, U.S. December CPI data released yesterday came in largely in line with expectations. Headline CPI rose 2.7% year over year and 0.3% month over month. Core CPI, however, undershot expectations and matched the prior reading, increasing 2.6% Y

In last night’s U.S. equity session, healthcare and pharmaceutical stocks posted broad-based strength, with related healthcare ETFs clearly outperforming the broader market. Against a backdrop of tech sector dispersion and more cautious market sentiment, healthcare has once again moved into focus for capital allocation. From both a fundamental and trading-logic perspective, the rebound in the healthcare sector is not accidental： The defensive profile is reasserting itself: Amid ongoing macro uncertainty, healthcare remains a classic non-cyclical, demand-inelastic sector. With stable cash flows and relatively low earnings volatility, healthcare assets tend to attract inflows when risk appetite moderates. Valuation repair has become a key driver: After the prior correction, overall valuation

Against a backdrop of heightened market volatility, the U.S. healthcare sector has maintained relatively resilient performance. Compared with the previous trading session, a pullback in overall risk appetite has led to a clearer internal differentiation among healthcare-related ETFs. Volatility remains more pronounced in biotechnology-focused products, while ETFs centered on large-cap pharmaceuticals and diversified healthcare have exhibited comparatively stable performance. Overall, the defensive characteristics of the healthcare sector continue to provide a degree of support under the current market environment. From an internal structural perspective, biotechnology-related ETFs have experienced relatively larger drawdowns, whereas products concentrated in large pharmaceutical companies

Lately, the question everyone keeps asking is pretty simple: “Gold has already run this far — is there still upside?”The most intriguing aspect of gold's recent performance isn't the magnitude of its gains, but its remarkable resilience after hitting historic highs—it simply refuses to fall. Many anticipated a sharp downward move, only to see the price consolidate at elevated levels. Today, gold reached a new all-time high of $4,722.78.Looking at gold ETFs, the overnight session tells the same story. $SPDR Gold ETF(GLD)$ was up 2.83%, $Gold Trust Ishares(IAU)$ gained 2.89%, and $VanEck Gold Miners ETF(GDX)$ jumped 3.83%. On the leveraged side,

Gold surged to a new all-time high of $5,311 today. Since the start of 2026, prices have rocketed more than 20%, climbing all the way from $4,332. Major gold-related ETFs have posted equally staggering gains. Among leveraged products, 3x long $MicroSectors Gold Miners 3x Leveraged ETN(GDXU)$ is up 100.5% YTD, while 2x long $Direxion Daily Junior Gold Miners Index Bull 2X Shares(JNUG)$ and $Direxion Daily Gold Miners Index Bull 2X Shares(NUGT)$ have gained 65% and 60.2%, respectively. In the gold miners space, $VanEck Gold Miners ETF(GDX)$ has risen 27.4% YTD. ETFs that directly track gold prices, such as